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Background: Remifentanil has been suggested for its short duration of action to replace standard opioids for
induction of general anaesthesia in caesarean section. While the stabilizing effect of remifentanil on maternal
circulation has been confirmed, its effect on postnatal adaptation remains unclear, as currently published studies
are not powered sufficiently to detect any clinical effect of remifentanil on the newborn.
Methods: Using a double-blinded randomized design, a total of 151 parturients undergoing caesarean delivery
under general anaesthesia were randomized into two groups – 76 patients received a bolus of remifentanil prior to
induction, while 75 patients were assigned to the control group. Remifentanil 1 μg/kg was administered 30 seconds
before the standard induction of general anaesthesia. The primary outcome measure was an assessment of neonatal
adaptation using the Apgar score, while secondary outcomes included the need for respiratory support after delivery
and differences in umbilical blood gas analysis (Astrup).
Results: The incidence of lower Apgar scores between 0 and 7 was significantly higher in the remifentanil group at
one minute (25% vs. 9.3% of newborns, p = 0.017); whilst at five minutes and later no Apgar score differences were
observed. There was no difference in the need for moderate (nasal CPAP) or intensive (intubation) respiratory support,
but significantly more neonates in the remifentanil group required tactile stimulation for breathing support (21% vs. 7%
of newborns, p = 0.017). There was no difference in the parameters from umbilical cord blood gas analysis between
the groups.
Conclusion: At a dose of 1 μg/kg, remifentanil prior to induction of general anaesthesia increases the risk of neonatal
respiratory depression during first minutes after caesarean delivery but duration of clinical symptoms is short.
Trial registration: ClinicalTrials.gov: NCT01550640.
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Opioids are routinely avoided during induction to gen-
eral anaesthesia for caesarean section because of the po-
tential for respiratory depression in the neonate [1,2].
On the other hand, insufficient depth of analgesia in
parturients until foetal delivery remains a concern for* Correspondence: jan.blaha@lf1.cuni.cz
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unless otherwise stated.obstetric anaesthetists [3,4]. Therefore, the ultra short-
acting μ1-receptor agonist remifentanil has been
suggested as a replacement for longer acting opioids in
parturients undergoing caesarean delivery [5-11]. Remi-
fentanil rapidly crosses the placenta but simultaneously
is quickly eliminated from the neonatal circulation by
degradation with nonspecific esterases in plasma and/or
redistribution [12-14]. With a half-life of 3–10 minutes,
remifentanil should be almost entirely eliminated from
foetal circulation by the time of delivery [15]. How-
ever, in obstetrics, despite promising pharmacokinet-
ics and pharmacodynamics, remifentanil is currentlyl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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labour analgesia rather than for general anaesthesia for cae-
sarean delivery [16].
While the stabilizing effect of remifentanil on maternal
circulation has been clearly and consistently described in
several studies, including the systematic review and
meta-analysis published by Heesen and colleagues [17],
the effect on postnatal adaptation remains unclear, as
these studies have not been sufficiently powered. We
therefore aimed our study primarily as a comparison of
postnatal adaptation of neonates after caesarean delivery
in parturients receiving remifentanil bolus of 1 μg/kg
prior to induction of general anaesthesia with those hav-
ing standard opioid-free induction.
Methods
Study design
This prospective, randomized, controlled, and double-
blinded study was conducted at a tertiary care university
hospital with an average of 4,600 births per year, in
the period between March 2011 and April 2014.The
study was approved by the Ethics Committee of the
General University Hospital in Prague (MZ10-UK1LF-
Slanar) and registered at the Clinical Trials Database
(ClinicalTrials.gov NCT01550640). Study was conducted
in accordance with Helsinki Declaration principles. Signed
informed consent was obtained from each participant.
Primary objective of the study was to compare new-
born postnatal adaptation in parturients undergoing
caesarean delivery under general anaesthesia with a
remifentanil bolus 1 μg/kg administered prior to the in-
duction of general anaesthesia with those undergoing
standard induction. Secondary outcomes were require-
ments for postoperative respiratory support of neonates
and differences in umbilical cord blood gas analysis.
Study population
Eligible patients were parturients undergoing caesarean
delivery under general anaesthesia. Patients were
screened and enrolled in the study by an anaesthetist
during the pre-anaesthesia visit before caesarean de-
livery. Inclusion criteria were: age of 18 – 45 years.
Exclusion criteria included known allergy to remifentanil,
multiple pregnancy, gestational age below the 35th week,
estimated weight of foetus below 2500 grams, severe foetal
hypoxia, severe maternal hypotension, and other serious
foetal or maternal conditions. Discontinuation criterion
was difficult foetal delivery defined as uterine incision-to-
delivery interval >3 min.
Study interventions
Parturients were randomly assigned to two study groups -
remifentanil (RMF) or standard (STD). Treatment alloca-
tion was performed using online randomization generator(www.randomization.com). Each patient was allocated
before entering the operating room. The randomization
was kept blinded for the patient, surgeon, and neonat-
ologist. Patients in the RMF group received a bolus of
remifentanil 1 μg/kg 30 seconds prior to induction with
thiopentone; while all other preoperative, anaesthetic,
obstetric and postoperative procedures, were identical
for both groups.
General anaesthesia
Standard departmental protocol for caesarean delivery
under general anaesthesia was used with metoclopra-
mide and ranitidine administered orally for aspiration
prevention. After preoxygenation, general anaesthesia
was induced using i.v. thiopentone 5 mg/kg followed by
succinylcholine 1.25 mg/kg, and, until delivery, main-
tained with sevoflurane at an expired concentration of
0.5-0.7% in a 50% gas mixture of nitrous oxide/oxygen.
After ligation of the umbilical cord, sufentanil 0.5 μg/kg
and atracurium 0.35 mg/kg were administered for anal-
gesia and muscle relaxation and sevoflurane was in-
creased to 1%.
Obstetric management
Pfannenstiel supra-cervical laparotomy and Geppert
uterotomy were used in all cases. Oxytocin 5 IU as a
bolus was administered intravenously, diluted in 20 ml
of saline after removal of the placenta.
Monitoring and evaluation
Intraoperative monitoring was performed using Datex
Ohmeda S/5 TM Compact Anaesthesia Monitor (Datex-
Ohmeda Inc., USA) according to general standards for
patient monitoring during general anaesthesia. Time 0
was determined as the time of remifentanil administra-
tion in the RMF group or time 30 sec prior to thiopen-
tone administration in the STD group. The following
parameters were monitored; systolic and diastolic non-
invasive blood pressure (NIBPsyst; NIBPdiast), mean
blood pressure (MAP), heart rate (HR), electrocardiog-
raphy (ECG) with ST segment analysis (lead II), pulse
oximetry (SpO2), capnography (EtCO2), % of oxygen and
volatile anaesthetic, and ventilation parameters (minute
ventilation, tidal volume, respiratory rate and maximal
inspiratory pressure). To evaluate the depth of anaesthesia,
continuous bispectral index analysis (BIS) was used.
Evaluation of newborn adaptation was performed
using Apgar scores at 1, 5 and 10 minutes, simultan-
eously with arterial and venous umbilical cord blood gas
analysis and clinical examination. Clinical assessment
was undertaken by an experienced neonatologist and
acid/base balance status was evaluated directly in the
delivery room with ABL 90 Flex (Radiometer Medical,
Denmark) blood gas analyser.
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The sample size of 150 parturients was calculated to de-
tect an overall twofold difference between the groups in
the primary outcome (Apgar scores 0–7) with a two-
sided 5% significance level and a power of 80%. For
sample size calculation, we used data from long term de-
partmental baseline statistics, where Apgar score of 0–7
was observed in 9.5% of caesarean sections under gen-
eral anaesthesia. A 36-month inclusion period was antic-
ipated to recruit this number of patients.
Statistical analysis was performed with the STATISTICA
10 software (StatSoft, Czech Republic). All data was tested
for normality using Kolmogorov-Smirnov test prior to final
analysis. Numerical data from both groups was compared
using Student’s t-test or Mann–Whitney Rank Sum Test,
as appropriate. For categorical variables the Fisher’s exact
test and chi-square test were used. All statistical tests were
performed two-tailed and values of P < 0.05 were consid-
ered statistically significant.
Results
A total of 151 parturients were included in the study, 76
patients were allocated to the remifentanil group while
another 75 were assigned to the standard group. All par-
ticipants were in physical status class I-II according to
the American Society of Anesthesiologists. Demographic
characteristics of parturients are expressed in Table 1.
Figure 1 represents study flow diagram.
The most frequent reason for employment of general
anaesthesia in this study was refusal of regionalTable 1 Characteristics of parturients and newborns
Remifentanil
group (n = 76)
Standard
group (n = 75)
P
Age (years) 33.1 ± 5.1 32.3 ± 5.3 0.362
Weight prior to pregnancy (kg) 68.1 ± 13.1 69.8 ± 13.4 0.473
Actual weight (kg) 82.0 ± 13.4 81.4 ± 14.3 0.813
Height (cm) 168.9 ± 6.8 167.6 ± 5.8 0.233
BMI (kg.m−2) 24.0 ± 4.4 24.9 ± 5.0 0.254
Medical concomitant diseases
Hypertension 6 (8%) 6 (8%) 0.981
Asthma 4 (5%) 3 (4%) 0.712
Thyreopathy 3 (4%) 3 (4%) 0.987
Diabetes 3 (4%) 2 (3%) 0.660
Placenta praevia centralis 3 (4%) 3 (4%) 0.987
Other 11 (14%) 13 (17%) 0.796
Newborns
Weight of newborns (g) 3162.9 ± 467 3122.5 ± 618 0.334
Gestational age (weeks) 38.6 ± 1.1 38.9 ± 1.4 0.541
Data are presented as mean ± standard deviation or n (%).
BMI = Body Mass Index.anaesthesia by the parturient (67 vs. 68 patients). In only
9 (RMF group) and 7 (STD group) cases, respectively,
the choice of general anaesthesia was based on medical
considerations - placenta praevia centralis (6 pts.),
thrombocytopenia (3 pts.), psychosis (3 pts.), tokophobia
(2 pts.), history of spinal trauma (1 pt.) and hypersensi-
tive tetany (1 pt.).
Anaesthesia and surgical baseline management charac-
teristics including delivery time (induction to delivery
interval) are shown in Table 2. No intra- or postop-
erative major complications were recorded during the
study.
Neonatal outcome
Table 3 and Figure 2 show the characteristics of neonatal
postnatal adaptation – Apgar scores and the need for re-
spiratory support. We noted a higher incidence of low
Apgar scores between 0 and 7 in the remifentanil group
at the first minute (19 vs. 7 newborns, p = 0.017), but
after the fifth minute no difference between the groups
was observed. No difference between the study groups
was found in requirement for moderate or intensive
respiratory support following delivery (p = 0.983). Tem-
porary CPAP (continuous positive airway pressure) ven-
tilation was employed in 10 newborns (5 in each group),
but none required intubation or admission to a neonatal
intensive care unit. There was however, a significant dif-
ference in the need for mild breathing support using
tactile stimulation during the first 5 minutes (16 vs. 5
newborns, p = 0.017) (Table 3). No newborn required ad-
ministration of an μ1-opioid receptor antagonist.
Table 4 shows umbilical cord arterial and venous
blood gas analysis. No difference was observed for any
parameter including number of pH values <7.2; such a
value was recorded only once (7.18, in the remifentanil
group).
Maternal haemodynamics
The study groups were equal in basal haemodynamic pa-
rameters (blood pressure and heart rate at time 0), but
they varied significantly at the time of intubation (both
blood pressure and heart rate) and delivery (heart rate).
The basal haemodynamic profiles are shown in Table 5.
Depth of anaesthesia
No difference was found between the groups after in-
duction of general anaesthesia in depth of anaesthesia
(BIS), ST-analysis, or respiratory-ventilation parameters
(SatO2, EtCO2). The profiles of BIS values are shown in
Table 2.
Discussion
Our study is not the first one to evaluate the effect
of remifentanil in parturients undergoing caesarean
Figure 1 Assessment, randomization, and follow-up of the study patients.
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knowledge, it is the only one adequately powered to
assess the effect on the incidence of respiratory de-
pression during postnatal adaptation of newborns.
Moreover, the other important aspect of our study is its
sample size. With 151 patients participating in the study
and 76 in the remifentanil group, this is the largest remi-
fentanil assessment in obstetric patients undergoing cae-
sarean delivery. The size of our homogenous study group
should be highlighted especially in comparison to the
meta-analysis conducted and published in 2013 by a
German-Belgian team with the inclusion of 186 patients
from 5 randomized clinical trials [17].
While published studies agree on the positive effect
of remifentanil on reducing adverse haemodynamicresponse to intubation and surgery during caesarean
delivery, they vary in terms of its effect on neonatal
adaptation. Yoo [18] and Ngan Kee [15] used an identi-
cal bolus of remifentanil - 1 μg/kg. They highlighted,
similarly to our study, a risk of transient, neonatal re-
spiratory depression. In contrast, Bouattour and col-
leagues did not demonstrate any attenuation of neonatal
adaptation after administration of 0.5 μg/kg of remifenta-
nil [19]. More worryingly, 14.3% of newborns in another
study had to be intubated for respiratory support, follow-
ing a pre-induction dose of remifentanil 0.5 μg/kg [20].
The determination of a remifentanil “safe dose”, not
causing adverse effect on neonate, was not even unrav-
elled by the aforementioned meta-analysis performed by
Heesen et al. [17].
Table 2 Data related to general anaesthesia
Remifentanil
group (n = 76)
Standard
group (n = 75)
P
Anaesthesia prior foetal delivery
Thiopentone bolus (mg) 398 ± 64 401 ± 68 0.745
Sevoflurane (%) 0.57 ± 0.2 0.58 ± 0.3 0.586
SatO2 (%) 98.4 ± 1.7 97.9 ± 2.3 0.219
ETCO2 (kPa) 4.5 ± 0.5 4.4 ± 0.4 0.529
Induction-to-delivery interval (min) 4.0 ± 1.4 3.9 ± 1.2 0.884
Duration of surgery (min) 43 ± 9.2 41 ± 9.4 0.724
Estimated blood loss (ml) 594 ± 196 576 ± 148 0.648
BIS (%)
Baseline 95.4 ± 4.3 96.2 ± 4.2 0.360
Tracheal intubation 52.4 ± 16 52.2 ± 12.9 0.930
Delivery 57.7 ± 13.7 55.7 ± 12.2 0.401
At 10 min after induction 58.3 ± 10.5 55.8 ± 12.3 0.231
Data are presented as mean ± standard deviation. Sevoflurane =mean end
expiratory concentration of sevoflurane from induction to delivery; SatO2 =mean
oxygen saturation from induction to delivery; ETCO2 = mean end tidal
capnography from induction to delivery; BIS = bispectral index analysis.
Baseline means time before induction to general anaesthesia.
Figure 2 Bar graph showing the need for management of
newborn respiratory depression. The bar graph plots the
percentage of newborns requiring each level of respiratory
stimulation or support (n = 76 in the remifentanil group and n = 75
in standard group). The black column represents the remifentanil
group; the cross-hatched column the control group. *P = 0.017.
CPAP = continuous positive airway pressure ventilation.
Table 4 Umbilical cord blood gas analysis
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dence of moderate to severe aggravation of neonatal
adaptation (Apgar scores 0–7) after remifentanil admin-
istration (p =0.017). However, in all cases, neonatal re-
spiratory depression lasted only for several minutes
because lower Apgar scores were observed at the 1st mi-
nute only. The Apgar scores were similar at 5 minutes,
which is a more crucial time for subsequent neonatal
care and/or eventual transfer to neonatal intensive care
unit. In total, 28% of neonates in the remifentanilTable 3 Neonatal outcome
Remifentanil
group (n = 76)
Standard
group (n = 75)
P value
Apgar score
1-minute 8.1 ± 2.0 8.9 ± 1.4 0.005
5-minute 9.2 ± 1.1 9.6 ± 0.8 0.022
10-minute 9.8 ± 0.5 9.8 ± 0.4 0.198
Apgar score 0 -7
1-minute 19 (25.0%) 7 (9.3%) 0.017
5-minute 5 (6.6%) 2 (2.7%) 0.442
10-minute 0 (0%) 0 (0%) -
Need for respiratory support
Tactile stimulation 16 (21.1%) 5 (6.7%) 0.017
CPAP 5 (6.6%) 5 (6.7%) 0.983
Mechanical ventilation 0 (0%) 0 (0%) -
Administration of naloxone 0 (0%) 0 (0%) -
Data are presented as mean ± standard deviation or n (%).
CPAP = continuous positive airway pressure ventilation.group required some form of respiratory support after
delivery, however they mostly responded only to tactile
stimulation.
The observed incidence of short-time lasting, deterio-
rated postpartum neonatal adaptation was quite high in
the remifentanil group, although its clinical significance
and severity are not clear. A hypothetical explanation of
different results in published studies could be the exist-
ence of genetic polymorphism of the placenta transport-
ing system glycoprotein P (multidrug resistance gene 1,Remifentanil
group (n = 76)
Standard
group (n = 75)
P value
Arterial
pH 7.3 ± 0.0 7.3 ± 0.0 0.210
pCO2 (kPa) 6.7 ± 0.7 6.6 ± 0.7 0.450
HCO3-act (mmol/l) 25.0 ± 1.9 24.9 ± 1.9 0.786
HCO3-std (mmol/l) 22.2 ± 1.9 22.0 ± 1.3 0.567
BE (mmol/l) −1.4 ± 1.7 −1.2 ± 1.7 0.645
pO2 (kPa) 2.8 ± 0.6 2.6 ± 0.6 0.189
satO2 (%) 41.9 ± 14.6 38.0 ± 13.6 0.137
Venous
pH 7.4 ± 0.0 7.3 ± 0.0 0.203
pCO2 (kPa) 5.8 ± 0.5 5.8 ± 0.6 0.721
HCO3-act (mmol/l) 23.5 ± 1.6 23.4 ± 1.9 0.848
HCO3-std (mmol/l) 22.4 ± 1.1 22.2 ± 1.4 0.421
BE (mmol/l) −1.7 ± 1.7 −1.8 ± 1.7 0.801
pO2 (kPa) 4.6 ± 0.8 4.3 ± 1.1 0.157
satO2 (%) 72.6 ± 10.4 68.3 ± 14.4 0.069
Data are presented as mean ± standard deviation.
Table 5 Maternal haemodynamic profiles
Remifentanil
group (n = 76)
Standard
group (n = 75)
P
Systolic blood pressure (mmHg)
Baseline 140.8 ± 16.2 140.6 ± 18.0 0.948
At intubation 145.4 ± 23.5 164.1 ± 26.4 <0.0001
At delivery 146.6 ± 22.5 149.9 ± 25.4 0.444
At 10 min after induction 125.7 ± 17.3 122.5 ± 17.0 0.283
Heart rate (bpm)
Baseline 89.4 ± 12.8 93.1 ± 16.9 0.187
At intubation 91.8 ± 16.6 109.7 ± 17.2 <0.0001
At delivery 88.9 ± 13.7 101.3 ± 20.1 <0.001
At 10 min after induction 73.0 ± 16.3 76.6 ± 14.7 0.204
Data are presented as mean ± standard deviation. Baseline means time before
induction to general anaesthesia.
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divergent transfer of remifentanil into the foetal circula-
tion [21,22]. Another reason for relatively higher inci-
dence of respiratory depression in our study may
also be shorter time of foetal delivery (4.0 min
induction-to-delivery time) compared to some other
centres [20,23,24]. We may hypothesize that remifen-
tanil with its half-life of 3–10 minutes was not com-
pletely eliminated at the time of delivery. This could
explain why Yoo et al. [24] found no significantly
higher depression rate, even with a dose of 1.25 μg/kg. It
should be noted that they reported interval to delivery
approximately 10 minutes, which is potentially longer
than expected effect of remifentanil.
It should be also highlighted that postnatal adaptation
of the newborn is affected by previous intrauterine foetal
condition, concurrent administration of thiopentone and
volatile anaesthetics, as well as by induction-to-delivery
interval and technique of caesarean section. Therefore
we excluded parturients with expected alteration of neo-
natal respiratory function (immaturity of foetus or in
utero pathologies). In order to decrease bias of the study,
we also excluded females with multiple pregnancy (risk
of low birth weight and prematurity) and newborns fol-
lowing difficult delivery with uterine incision-to-delivery
interval more than 3 min [25-27]. Nevertheless, we ob-
served 14% incidence of moderate respiratory depression
even in the standard group, with 5 newborns requiring the
use of CPAP. Specific reasons for this depression remain
unclear even after detailed analysis of individual cases (with
no noted significant differences in delivery interval, gesta-
tional age or weight, blood gas analysis results or maternal
demographic, respiratory or haemodynamic parameters).
In contrast to other studies, we did not find any differ-
ence in the umbilical cord blood gas analysis parameters,
including Base Excess reported in Heesen’s meta-analysis[17]. Acid/base balance parameters in umbilical cord
blood correspond with the status of foetal oxygenation at
the time of delivery. We detected only one newborn in the
remifentanil group presenting with pH <7.2, which may
be associated with increased neonatal morbidity [28].
Therefore, our assessment of remifentanil effect on neo-
natal adaptation should not have been affected by concur-
rent foetal intrauterine hypoxia.
We are aware of limitations of our study. Although
the adaptation of each newborn was evaluated by experi-
enced neonatologist, requirements to stimulate their
breathing by tactile stimulation might still be biased by
inter-individual differences. Another limitation may be
exclusion of deliveries indicated for acute foetal hypoxia.
General anaesthesia is most commonly administered in
such cases, where suppression of stress response to tra-
cheal intubation and surgical stimuli would be theoretic-
ally desirable.
Forming a consensus with other published trials, we
also recorded the positive effect of remifentanil on the
suppression of cardiovascular stress response to tracheal
intubation and surgery. A dose of remifentanil 1 μg/kg
given 30 seconds prior to induction of general anaesthe-
sia effectively reduced a rise in both blood pressure and
heart rate until delivery of foetus. Whereas the haemo-
dynamic monitoring wasn’t the main aim of this study, it
was not blinded for anaesthesiologist. Therefore its as-
sessment might be burdened by a potential bias, albeit
most likely only an insignificant. The haemodynamic
profile herein is given primarily within an overall de-
scription of intraoperative course of our study.
Unlike its stabilizing effect on the cardiovascular sys-
tem, the dose of remifentanil 1 μg/kg did not affect the
depth of anaesthesia. BIS values were below 60 in both
groups throughout the study. This value has been ac-
cepted as a threshold which should decrease the inci-
dence of awareness [29,30]. Similar results have been
reported in other studies [18]. It is assumed that the ma-
jority of hypnotic effect during induction is achieved by
the initial dose of thiopentone potentiated by anaesthetic
gases, while remifentanil in this dose has only small ef-
fect on depth of anaesthesia [31].
Conclusion
We demonstrated that a pre-induction dose of remifen-
tanil 1 μg/kg is associated with a relatively high risk of
neonatal respiratory depression. However, this attenu-
ation was present only in the first five minutes after de-
livery and its clinical significance seems to be rather
mild. Remifentanil is a suitable choice of co-induction
agent in parturients who could be prone to excessive
hypertension and tachycardia during induction to anaes-
thesia. In these cases, careful postnatal care must be ap-
plied if respiratory depression is observed.
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